NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/13/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,644.4 mln
Float108 mln
Earnings Date08/19/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-3.6
Highly reliable
1-Year Forecast
35.77
Exceptional upside
Relative Strength
94
/ 100
Top performer
Debt / Equity
0.01
Debt-free
ROE
-54.42
Deeply negative
Business Description
Immunome is a US-based cancer drug company focused on developing treatments that target tumors more precisely and with fewer side effects. Its most advanced programs include a Phase 3 drug for a rare connective tissue cancer called desmoid tumors and an early-stage therapy that delivers toxic payloads directly to cancer cells. The company is also working on several earlier-stage treatments designed to attack solid tumors through different biological pathways. Founded in 2006 and headquartered in Bothell, Washington, Immunome is building a broad pipeline aimed at improving outcomes for cancer patients.
